Oscillators: RSI_6 at 12.23 = extremely oversold, but oversold alone is not a buy signal without reversal confirmation.
Key levels: Support S1 = 0.855 (near current 0.8784); if it breaks, next support S2 = 0.738. Resistance levels to reclaim for any meaningful reversal: Pivot 1.044, then R1 1.234.
Recent tape: Regular session -8.06% with small pre-market bounce (+3.61%) suggests weak underlying demand.
Pattern-based forecast provided: ~40% chance of slight further drift down next day/week; modest +2.37% next month estimate is not strong enough to override the current downtrend.
Positive Catalysts
holds.
Neutral/Negative Catalysts
No news in the past week: lack of catalysts makes it harder to reverse sentiment quickly.
Financial Performance
Latest quarter: 2025/Q3.
Revenue: 0 (no meaningful topline traction).
Net income: -2.806M, down 76.91% YoY (loss widened materially).
EPS: -0.19, down 97.54% YoY (significant deterioration).
Overall: financials show worsening profitability with no revenue growth base to lean on, which generally undermines dip-buying.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating or price target change data was provided, so no confirmed recent Wall Street upgrades/downgrades can be cited.
Wall Street-style pros view (inferred): potential optionality typical of small biotech names if pipeline progress occurs.
Wall Street-style cons view (data-driven): absence of revenue and sharply worse YoY earnings profile make the risk/reward unattractive without a clear catalyst or reversal signal.
Wall Street analysts forecast ALLR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALLR is 9.5 USD with a low forecast of 9.5 USD and a high forecast of 9.5 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast ALLR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALLR is 9.5 USD with a low forecast of 9.5 USD and a high forecast of 9.5 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.810
Low
9.5
Averages
9.5
High
9.5
Current: 0.810
Low
9.5
Averages
9.5
High
9.5
Ascendiant
NULL -> Buy
initiated
$9
AI Analysis
2025-07-28
Reason
Ascendiant
Price Target
$9
AI Analysis
2025-07-28
initiated
NULL -> Buy
Reason
Ascendiant initiated coverage of Allarity with a Buy rating and $9 price target. The firm sees large market opportunities for the company's DRP platform and Stenoparib drug. It believes positive clinical trial data in 2025 and 2026 will be catalysts for the shares.
